Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals

United European Gastroenterology Journal

Volumn 2, Issue 3, 2014, Pages 216-225

  Renner, Olga ^a   Harsch, Simone ^a   Matysik, Silke ^b   Lütjohann, Dieter ^c   Schmitz, Gerd ^b   Stange, Eduard F ^d  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Bile acid transport absorption; Bodyweight; Entric hormone; Expression; Intestine

Indexed keywords

26 HYDROXYCHOLESTEROL; 7ALPHA HYDROXYCHOLESTEROL; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; FIBROBLAST GROWTH FACTOR 19; GLYCINE; LITHOCHOLIC ACID; MESSENGER RNA; PROTEIN; TAUROCHENODEOXYCHOLIC ACID; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILE ACID SYNTHESIS; BODY MASS; CHOLELITHIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 85006210699     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640614527938     Document Type: Article

References (45)

1. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002; 143: 1741–1747.
2. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003; 17: 1581–1591.
3. Choi M, Moschetta A, Bookout AL, et al. Identification of a hormonal basis for gallbladder filling. Nat Med 2006; 12: 1253–1255.
4. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999; 11: 729–735.
5. Zweers SJ, Booij KA, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012; 55: 575–583.
6. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004; 145: 2594–2603.
7. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217–225.
8. Kong B, Wang L, Chiang JY, et al. Mechanism of tissuespecific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012; 56: 1034–1043.
9. Kliewer SA and Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002; 43: 359–364.
10. Wistuba W, Gnewuch C, Liebisch G, et al. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J Gastroenterol 2007; 13: 4230–4235.
11. Lundasen T, Galman C, Angelin B, et al. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J Intern Med 2006; 260: 530–536.
12. Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189–1194.
13. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm Bowel Dis 2011; 17: 1322–1327.
14. Schaap FG, van der Gaag NA, Gouma DJ, et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009; 49: 1228–1235.
15. Mraz M, Lacinova Z, Kavalkova P, et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol Res 2011; 60: 627–636.
16. Pattni SS, Brydon WG, Dew T, et al. Fibroblast growth factor 19 and 7alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin Transl Gastroenterol 2012; 3: e18.
17. Berr F, Pratschke E, Fischer S, et al. Disorders of bile acid metabolism in cholesterol gallstone disease. J Clin Invest 1992; 90: 859–868.
18. Honda A, Yoshida T, Tanaka N, et al. Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones. Gastroenterol Jpn 1993; 28: 406–414.
19. Duane WC, Hartich LA, Bartman AE, et al. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid inpatients with hypertriglyceridemia. J Lipid Res 2000; 41: 1384–1389.
20. Bergheim I, Harsch S, Mueller O, et al. Apical sodium bile acid transporter and ileal lipid binding protein in gallstone carriers. J Lipid Res 2006; 47: 42–50.
21. Renner O, Harsch S, Strohmeyer A, et al. Reduced ileal expression of OSTalpha-OSTbeta in non-obese gallstone disease. J Lipid Res 2008; 49: 2045–2054.
22. Renner O, Lutjohann D, Richter D, et al. Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease. BMC Gastroenterol 2013; 13: 30.
23. Zamboni M, Mazzali G, Zoico E, et al. Health consequences of obesity in the elderly: a review of four unresolved questions. Int J Obes (Lond) 2005; 29: 1011–1029.
24. Lechleitner M. Obesity and the metabolic syndrome in the elderly – a mini-review. Gerontology 2008; 54: 253–259.
25. Kuczmarski RJ and Flegal KM. Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr 2000; 72: 1074–1081.
26. Hemmelmann C, Brose S, Vens M, et al. Percentiles of body mass index of 18–80-year-old German adults based on data from the Second National Nutrition Survey. Dtsch Med Wochenschr 2010; 135(17): 848–852.
27. Babiarczyk B and Turbiarz A. Body Mass Index elderly people - reference ranges matter. Prog Health Sci 2012; 2: 58–67.
28. Renner O, Harsch S, Schaeffeler E, et al. Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expression. Hum Genet 2009; 125: 381–391.
29. Geick A, Eichelbaum M and Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581–14587.
30. Hahn C, Reichel C and von Bergmann K. Serum concentration of 7 alpha-hydroxycholesterol as an indicator of bile acid synthesis in humans. J Lipid Res 1995; 36: 2059–2066.
31. Scherer M, Gnewuch C, Schmitz G, et al. Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3920–3925.
32. van Schaik FD, Gadaleta RM, Schaap FG, et al. Pharmacological activation of the bile acid nuclear farnesoid X receptor is feasible in patients with quiescent Crohn’s colitis. PLoS One 2012; 7: e49706.
33. Matysik S, Martin J, Bala M, et al. Bile acid signaling after an oral glucose tolerance test. Chem Phys Lipids 2011; 164: 525–529.
34. Herrera J, Amigo L, Husche C, et al. Fecal bile acid excretion and messenger RNA expression levels of ileal transporters in high risk gallstone patients. Lipids Health Dis 2009; 8: 53.
35. Song KH, Li T, Owsley E, et al. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49: 297–305.
36. Fang Q, Li H, Song Q, et al. Serum fibroblast growth factor 19 levels are decreased in Chinese subjects with impaired fasting glucose and inversely associated with fasting plasma glucose levels. Diabetes Care 2013; 36: 2810–2814.
37. Eren F, Kurt R, Ermis F, et al. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin Biochem 2012; 45: 655–658.
38. Gerhard GS, Styer AM, Wood GC, et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care 2013; 36: 1859–1864.
39. Bennion LJ and Grundy SM. Effects of obesity and caloric intake on biliary lipid metabolism in man. J Clin Invest 1975; 56: 996–1011.
40. Mabee TM, Meyer P, DenBesten L, et al. The mechanism of increased gallstone formation in obese human subjects. Surgery 1976; 79: 460–468.
41. Leijd B. Cholesterol and bile acid metabolism in obesity. Clin Sci (Lond) 1980; 59: 203–206.
42. Mok HY and Grundy SM. Cholesterol and bile acid absorption during bile acid therapy in obese subjects undergoing weight reduction. Gastroenterology 1980; 78: 62–67.
43. Einarsson K, Hellstrom K and Kallner M. Bile acid kinetics in relation to sex, serum lipids, body weights, and gallbladder disease in patients with various types of hyperlipoproteinemia. J Clin Invest 1974; 54: 1301–1311.
44. Dostalova I, Kavalkova P, Haluzikova D, et al. Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 2008; 93: 3627–3632.
45. Stejskal D, Karpisek M, Hanulova Z, et al. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand J Clin Lab Invest 2008; 68: 501–507.